Andrimid is a hybrid nonribosomal peptide-polyketide antibiotic that blocks the carboxyl-transfer reaction of bacterial acetyl-CoA carboxylase (ACC) and thereby inhibits fatty acid biosynthesis with submicromolar potency. The andrimid biosynthetic gene cluster from Pantoea agglomerans encodes an admT gene with homology to the acetyl-CoA carboxyltransferase (CT) ␤-subunit gene accD. Escherichia coli cells overexpressing admT showed resistance to andrimid. Co-overproduction of AdmT with E. coli CT ␣-subunit AccA allowed for the in vitro reconstitution of an active heterologous tetrameric CT A 2T2 complex. A subsequent andrimidinhibition assay revealed an IC 50 of 500 nM for this hybrid A2T2 in contrast to that of 12 nM for E. coli CT A 2D2. These results validated that AdmT is an AccD homolog that confers resistance in the andrimid producer. Mutagenesis studies guided by the x-ray crystal structure of the E. coli A 2D2 complex disclosed a single amino acid mutation of AdmT (L203M) responsible for 5-fold andrimid sensitivity (IC 50 ‫؍‬ 100 nM). Complementarily, the E. coli AccD mutant M203L became 5-fold more resistant in the CT assays. This observation allowed for bioinformatic identification of several Vibrio cholerae strains in which accD genes encode the Met7Leu switches, and their occurrences correlate predictively with sensitivities to andrimid in vivo.
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antibiotic resistance ͉ fatty acid biosynthesis inhibitor T he inevitable emergence of antibiotic resistance is of major health concern and demands continuous efforts for the discovery of new antibiotics (1) . The generation of new classes of antibiotics calls for the identification of novel molecular scaffolds and necessitates detailed understanding of antibiotictarget interactions as well as antibiotic-resistance mechanisms to sustain future developments. Andrimid and moiramide (Fig. 1A) belong to a new class of natural antibiotics with a hybrid nonribosomal peptide polyketide scaffold that is acylated at the N terminus and modified by a pyrrolidinedione moiety at the C terminus. Member of this class of pseudopeptidic pyrrolidinedione molecules are widely distributed in nature (2) (3) (4) (5) and have received renewed attention when their cellular target was identified to be the bacterial acetyl-CoA carboxylase (ACC) (6) . ACC is an essential enzyme that catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the first committed step of fatty acid biosynthesis (7) . The reaction catalyzed by ACC comprises two distinctive half-reactions involving three catalytic components (Fig. 1B) . Biotin carboxylase (BC) catalyzes the initial step that transfers a carboxyl group to the biotin carboxyl carrier protein (BCCP). The carboxyltransferase (CT) is responsible for the subsequent transfer of the carboxyl group from biotin on the BCCP to acetyl-CoA to form malonyl-CoA. In contrast to mammalian ACCs, where the three enzymatic components reside in a single polypeptide chain (7), bacterial ACC is dissociated into separate subunits. In Escherichia coli, monomeric BC and homodimeric BCCP are encoded by accB and accC genes (8-10), whereas heterotetrameric (␣ 2 ␤ 2 ) CT is encoded by accA (CT ␣-subunit) and accD (CT ␤-subunit) genes (Fig. 1B) (11, 12) . The lack of primary sequence homology between the prokaryote and eukaryote forms of ACC plus their clear structural distinctions have made bacterial ACC a longappreciated target for antibacterial drug discovery (13) . However, no viable medicinal lead was discovered until 2004, when andrimid and moiramide were identified as potent inhibitors of the CT step of the bacterial ACC-catalyzed reactions.
The biosynthetic gene cluster for andrimid in Pantoea agglomerans has been identified and sequenced to reveal 21 genes (Fig. 1C) , the majority of which could be functionally assigned by bioinformatic analyses (14) . Subsequent heterologous expression of several ORFs in E. coli allowed for the in vitro reconstitution of the early biosynthetic pathway and the identification of the function of a transglutaminase homolog, AdmF, as a new condensation catalyst in the enzymatic assembly line (15) . The disclosure of the andrimid biosynthetic gene cluster also provided clues on how the andrimid producer acquires immunity to the antibiotic. Previous study showed that the andrimid-sensitive E. coli strain became resistant to andrimid when overexpressing admQ, which encodes a homolog of major facilitator subfamily transporter responsible for the antibiotic efflux (14) . The penultimate ORF in the andrimid biosynthetic gene cluster is admT, a gene that bears homology to E. coli accD (Fig.  1C) . Because andrimid targets bacterial acetyl-CoA CT, we hypothesized that admT encodes a resistant form of acetyl-CoA CT ␤-subunit that thereby acts as a second mechanism for the self-protection of andrimid producers. Here, we report the detailed in vivo and in vitro biochemical characterization of AdmT that validates our postulation. Mutagenesis studies on AdmT led us to identify key amino acid residues that contribute to the resistance, which subsequently allowed for the prediction of andrimid resistance among other bacterial strains. Overall, this study provides insight into the resistance mechanisms of andrimid and the binding mode of andrimid and moiramide with bacterial acetyl-CoA CT.
Results
Function Validation of AdmT. We initially set out to test the function of AdmT in vivo by overexpressing AdmT in E. coli BL21 cells. A disk diffusion antibiotic assay clearly showed notable resistance to andrimid in comparison with E. coli cells containing an empty expression vector ( Fig. 2A) , indicating that AdmT can efficiently recruit E. coli AccA in vivo and form an active heterotetrameric [(AccA) 2 (AdmT) 2 ] CT that is less sensitive to andrimid. This observation prompted us to overproduce AdmT with AccA for subsequent in vitro characterization. The overproduction of the AccA/AdmT complex was carried out as described previously for AccA/AccD (11). The accA and admT genes were cloned as a single operon on the basis of the template of accA/accD genes in pET16b vector to allow for the stoichiometric expression of both proteins (see Materials and Methods). Purification relied on the polyhistidine tag encoded at the N terminus of AccA on nickel-nitrilotriacetic acid (Ni-NTA) agarose (Fig. 2B ). Both AccA/AccD and AccA/AdmT complexes yielded Ͼ20 mg of soluble proteins per liter of E. coli culture and diminished the potential endogenous E. coli AccA binding to Ͻ0.1% (11, 16) .
The activity of the overproduced AccA/AdmT complex was subsequently assessed spectrophotometrically on the basis of the reverse reaction, CT-catalyzed decarboxylation of malonyl-CoA (see Materials and Methods). Biocytin (in excess) was used as a BCCP surrogate (11, 16) . The production of acetyl-CoA was coupled to the citrate synthase/malate dehydrogenase reaction cycle, which requires NAD ϩ reduction and was monitored at 340 nm (11, 16) . Kinetic analyses of AccA/AdmT revealed an apparent K m of 149 Ϯ 26 M for malonyl-CoA and 5.1 Ϯ 0.5 mM for biocytin, indicating that the purified AccA/AdmT forms an active CT with catalytic efficiency comparable to that of the E. coli AccA/AccD pair (6, 11) . The sensitivity of AccA/AdmT to andrimid was tested in vitro by IC 50 measurement. In contrast to E. coli AccA/AccD with an IC 50 value of 12 nM to andrimid, AccA/AdmT complex is nearly 50-fold more resistant to andrimid (IC 50 ϭ 500 nM) (Fig. 2C) . The result correlates with the in vivo disk assay qualitatively, validating that AdmT is an andrimid-resistant CT ␤-subunit.
Identification of the Amino Acid Determinant in AdmT That
Contributes to Andrimid Resistance. Having established that AdmT constitutes an active CT ␤-subunit that is resistant to andrimid both in vivo and in vitro, we sought to examine the underlying molecular mechanism. AdmT shares close homology to E. coli AccD with a 36 amino acid residue difference along the 306-residue-length polypeptide chain (Fig. 3A) , which opened the question of whether a particular (set of) amino acid residue(s) is (are) important for the resistance.
A 3.2-Å resolution x-ray crystal structure of E. coli CT, recently disclosed by Waldrop and coworkers (17), served as the entry point for us to approach this problem. Although the available E. coli AccA/AccD structure was solved without any substrate, the knowledge gained in the structural studies of other biotin-dependent carboxylases, including Saccharomyces cerevisiae and Streptomyces coelicolor CTs (18, 19) , allows portrayal of the E. coli CT catalytic platform as the interfacial six-helix bundle region between its ␣-and ␤-subunits. Amino acid residues from Leu-174 to Leu-212 in the AccD polypeptide chain constitute the catalytic region in the CT ␤-subunit (Fig. 3B) . Among the 36 amino acid residues that are different between AccD and AdmT, only four fall in the putative catalytic site (Fig.  3) . Because andrimid has been determined to be a competitive inhibitor of malonyl-CoA (6), we envisaged that any of the four amino acids mentioned above (Asn-200, Leu-203, Leu-210, and Gly-211) could play a key role in andrimid resistance. Six AdmT mutants were generated through single and double amino acid substitutions that corresponded to the residues of E. coli AccD (Table 1 , entries 2-7). The andrimid sensitivity of the resulting AdmT variants was assessed qualitatively in E. coli BL21 cells by using the disk diffusion antibiotic assay.
AdmT variants harboring the L203M substitution became notably more sensitive to andrimid (Table 1 , entries 2 and 4), whereas the alteration of the remaining three residues (Asn-200, Leu-210, and Gly-211) did not produce any apparent effects (Table 1 , entries 3 and 5-7). This observation was validated further by using the in vitro inhibition assay. AdmT mutants were overproduced in E. coli with AccA and purified to homogeneity. IC 50 measurements revealed that AccA/AdmT(L203M) and AccA/AdmT(N200D/ L203M) are both 5 times more sensitive to andrimid than the wild-type (WT) AccA/AdmT complex (IC 50 ϭ 500 nM) ( Table 1 , entries 1, 2, and 4). In contrast, the IC 50 of the other AdmT mutants remained unchanged (Table 1, entries 5-7) .
With this quantification of the role of L203M mutation in AdmT on its susceptibility to andrimid, we then sought to test whether the reverse introduction of such a mutation into the WT E. coli AccD would result in increased tolerance for the antibi- otic. Again, we resorted to the disk diffusion antibiotic assay, which allowed direct visual assessment of the sensitivity of WT AccD and their mutants to andrimid. Resistance was clearly observed around the assay disk with 2.5-7.5 g of andrimid deposited, when the E. coli cells were overexpressed with AccD(M203L), compared with AccD(WT) ( Table 1 , entries 8 and 9). A similar resistance effect was observed when E. coli overexpressed AccD(S207Y) ( Table 1 , entry 10), a mutation identified in an andrimid-resistant E. coli strain that was previously created intentionally by serial transfers of growing cultures at sublethal antibiotic concentrations (6) . AccD(M203L) and AccD(S207Y) were subsequently overproduced in E. coli with AccA for the in vitro inhibition assay. IC 50 measurements further validated again andrimid resistance, because AccD(M203L) and AccD(S207Y) increased Ϸ5-and 8-fold in resistance (IC 50 ϭ 55 and 95 nM, respectively), compared with AccD(WT) (IC 50 ϭ 12 nM) ( Table 1 , entries [8] [9] [10] .
Along with the in vitro inhibition assays, kinetic analyses of the overproduced CTs and their mutants refined the effects of the mutations on the functions of these enzymes (Table 2) . Although all overproduced CTs shared a similar apparent K m for malonylCoA, their catalytic efficiencies varied: the k cat /K m values of AdmTs containing the L210F mutation and AccD(S207Y) were Ϸ6-fold lower than those of the WT AdmT and AccD subunits. Inspection of the x-ray crystal structure of E. coli AccA/AccD revealed that the Ser-207 residue in AccD and Leu-210 residue in AdmT are not surface-exposed but, rather, buried inside the presumptive catalytic pocket [supporting information (SI) Fig. S1 ]. Alteration of such residues might have an effect on the conformation of the intersubunit active site and, thereby, the catalytic efficiency. In contrast, the Leu-203 residue in AccD (or Met-203 in AdmT) is located on the protein surface (Fig. S1) Identification of Other Andrimid-Resistant Bacterial Strains. We envisioned that the 203-Met7Leu switch in AdmT and AccD might be used as a probe for the identification of other andrimidresistant bacterial strains. Accordingly, a protein BLAST search using AdmT amino acid sequence 191-214 was performed and allowed for the identification of Ͼ10 bacterial strains, the AccD sequences of which have the signature 203MGGVSAV209 motif (details not shown). In particular, several Vibrio cholerae strains (V. cholerae 1587, 623-39, and MZO-3) have the distinctive Met-203 residue in their AccDs, whereas other V. cholerae strains such as N16961 have the Leu-203 residue (Fig. 4A) . A subsequent disk diffusion assay showed that V. cholerae N16961 was sensitive to andrimid, whereas V. cholerae 1587, 623-39, and MZO-3 are resistant. (Fig. 4B, typical results shown) .
Discussion
The emergence of antibiotic-resistant microbial pathogens, as a destined fate of the persistent usage of antibiotics in modern-day living, requires constant effort to discover new antibiotics and understand the mechanisms of antibiotic resistance. Prominent examples of antibiotic-resistant microbes are the native antibiotic producers themselves. They are excellent models for studying antibiotic-resistance mechanisms because producing organisms evolve their own survival strategies to avoid self-destruction during antibiotic biosynthesis. Although the majority of the self-protective strategies exploited by antibiotic-producing microbes involve intracellular antibiotic modification, cellular target modification, and antibiotic efflux (20) (21) (22) , several antibiotic producers have been known to encode antibiotic-resistant target enzymes that contribute to their survival. The bacterial producers of DNA gyrase inhibitors such as aminocoumarins and albicidins are known to encode DNA gyrase-resistant genes that contribute to their self-protection (23, (24) (25) (26) , although the molecular mechanism underlying these resistances is still unknown. The D-cycloserine producer Streptomyces lavendulae has been shown to encode an antibiotic-resistant alanine racemase (ALR) that manifests a slower enzymatic conversion to the final cycloserine pyridoxal derivatives that inhibit the catalytic activity of ALR (27, 28) .
Andrimid and moiramide belong to a novel class of natural products with a pseudopeptide pyrrolidinedione backbone. They were identified recently as first-in-class potent inhibitors of the bacterial ACC via specific blockade of the CT-catalyzed halfreaction with nanomolar potency (6) . Subsequent structureactivity relationship studies led to analogues with modified pseudopeptide motifs and improved efficacies in vivo and in vitro (29, 30) . However, a detailed picture of their interactions with the target bacterial CTs in the first committed step of fatty acid biosynthesis remains elusive.
In this work, we studied the function of the admT gene encoded in the andrimid biosynthetic gene cluster and demonstrated that AdmT constitutes an andrimid-resistant form of the CT ␤-subunit and contributes to the survival of P. agglomerans during the production of andrimid. Initial development of an in vivo assay, by overexpressing AdmT in E. coli cells coupled with the disk diffusion antibiotic assay, allowed for direct visual examination of its andrimid-resistant nature. Subsequent overproduction of AdmT in E. coli by coexpression with E. coli AccA reconstituted an in vitro active heterotetrameric (AccA) 2 (AdmT) 2 protein complex. Inhibition assays by IC 50 measurement quantitated the resistant nature of AdmT; its IC 50 (500 nM) is Ϸ50 times more than that of AccD (12 nM).
Guided by the x-ray crystal structure of E. coli AccA/AccD (17), we focused on the four amino acid residue differences between AdmT and AccD that fall in the putative catalytic center of E. coli CT. Mutagenesis studies, coupled with the established in vivo and in vitro assays, allowed us to identify that the L203M mutation in AdmT confers a 5-fold andrimid-sensitivity recovery. Introduction of such a mutation in a reverse fashion to the WT E. coli AccD in turn gave a 5-fold increase in andrimid resistance. It is noteworthy that the AccD(M203L) mutant has an andrimid-resistant profile (i.e., IC 50 ) that is comparable with that of AccD(S207Y), a mutant previously isolated by serial passing of sublethal concentration of an andrimid analogue to E. coli cultures (6). Structure modeling of E. coli AccA/AccD suggests that the Met-/Leu-203 residue in AccD or AdmT is surface-exposed. Because this residue also locates next to Gly-204-Gly-205, which are postulated to stabilize the anionic intermediate involved in carboxyl-transfer process of the CTcatalyzed reaction (17, 18) , it is reasonable to speculate that the Met-/Leu-203 residue in AccD or AdmT is an important residue for the interaction with andrimid or substrate acetyl-CoA.
The L203M substitution in AdmT, however, does not fully mirror the andrimid-resistance profiles of AdmT in comparison with AccD. Additive and cooperative effects of other key residues around the AdmT catalytic core are likely responsible for such discrepancy. A valuable insight will assuredly be provided by the x-ray cocrystal structures of AccA/AdmT and AccA/AccD complexed with andrimid.
The recognition of Met7Leu switches in AccD and AdmT in modulating sensitivities to andrimid allowed us to use it as a signature probe to identify several V. cholerae bacterial strains that, on examination, are resistant to andrimid. By close examination of the genomes of these V. cholerae strains, it was noticed that all of the andrimid-sensitive strains encode two CT ␤-subunit genes, among which one is predictively resistant to andrimid but the other is sensitive. The andrimid gene clusters from P. agglomerans (14) and Vibrionales SWAT-3 (5) both encode transposases at the boundaries of the clusters that are likely responsible for horizontal gene transfer (HGT). Although this fact may explain the wide distribution of andrimid-and moiramide-producing Gram-negative bacteria in diverse ecological niches, it also suggests that the resistant accD genes that occur in several V. cholerae strains may have been acquired through HGT. The emergence of andrimid resistance, through HGT and as shown here by simple point mutation, raises likely resistance pathways for andrimid and derivatives if they progress to clinical development. Understanding the molecular interactions of the pseudopeptide pyrrolidinedione molecules with bacterial CT targets will be critical in the development of efficacious andrimid derivatives that are less susceptible to such a self-protective mechanism of antibiotic resistance.
Materials and Methods
Materials. Andrimid was isolated from P. agglomerans as described previously (14) , and the purity (Ͼ95%) was determined by HPLC and 1 H NMR analysis. L-Malate, biocytin, malonyl-CoA, NAD, BSA, L-malate dehydrogenase (from porcine heart), and citrate synthase (from porcine heart) were purchased from Sigma. E. coli BL21 DE3 cells (for protein overproduction) were purchased from Invitrogen. E. coli NovaBlue DE3 cells (for general cloning purpose) and pET-16b plasmid were obtained from Novagen. pQTev plasmid was obtained from the Protein Structure Factory.
Cloning. accD and admT genes were amplified from plasmid pSJ9 (12) and cosmid 2194C1 (14) by using primers 1-3 (Table S1 ) and ligated into the BglII and NotI sites of expression vector pQTev to give plasmids pXL90 and pXL91. For the in vitro assay of AccD and AdmT activities, they were cloned as one operon with the E. coli accA gene, respectively. A chimeric accA/accD gene containing an XhoI restriction site and a ribosomal binding site in between was first constructed as described previously (11) . In brief, accA and accD genes were amplified from plasmids pLS151 (31) and pSJ9 by using primers 4 -7 (Table S1 ) and overlap-extended by using primers 4 and 7 to give the target chimeric accA/accD gene. This gene was ligated into the NdeI and BamHI sites of expression vector pET16b to give plasmid pXL92. The admT gene was then amplified from cosmid 2194C1 by using primers 8 and 9 (Table S1 ) and ligated to the XhoI and BamHI sites of pXL92 to give plasmid XL93.
Site-Directed Mutagenesis. The mutants of AccD and AdmT for in vivo and in vitro bioassays were generated by using a Stratagene QuikChange Multi site-directed mutagenesis kit with plasmids pXL90 -pXL93 as the templates and primers 10 -17 (Table S1 ).
In Vivo Assay for Andrimid Sensitivity. E. coli BL21 DE3 cells were transformed with pXL90, pXL91, and their mutant derivatives and grown in LB medium supplemented with ampicillin (100 g/ml). Cells were grown at 37°C to an OD600 of Ϸ0.6 and then induced at 30°C with 1 mM isopropyl ␤-Dthiogalactoside and grown for an additional 4 h at 30°C. The expression levels of the AdmT or AccD (WT and mutant) proteins were assessed by SDS/PAGE and determined to be similar in all cell-culture extracts. Varied amounts of andrimid (5 mg/ml in DMSO) were deposited on the blank sterile concentration disk (Difco) on LB agar plates containing ampicillin (100 g/ml). The plates were then oversprayed with the 1:100 (vol/vol) aqueous dilution of the induced E. coli culture and incubated at 30°C overnight and at room temperature for 2 days. Plate images were acquired by using a multilight imager (Alpha Innotech). Inhibition-zone diameters were measured manually and defined as the nearest point from the disk at which a visible reduction of bacterial growth occurred. For V. cholerae strains, the andrimid-spotted LB agar plates were oversprayed with 1:100 (vol/vol) aqueous dilution of the overnight-grown V. cholerae cell cultures. The plates were then incubated at 30°C overnight, and images were acquired accordingly.
Protein Overproduction. The His-tagged AccA/AccD, AccA/AdmT, and their mutant protein complexes were overproduced in E. coli BL21 DE3 in a manner analogous to that described previously (11) . The proteins were purified to apparent homogeneity by Ni-NTA agarose column and buffer-exchanged to 25 mM Hepes (pH 7.5) and 500 mM NaCl. Protein concentrations were determined by using the Bradford assay. Proteins were aliquot-flash-frozen in liquid nitrogen and stored at Ϫ80°C. The overproduction yields for each protein were typically 20 -25 mg/liter.
In Vitro CT Activity and Inhibition Assay. The CT activity was monitored in the reverse direction, where the production of acetyl-CoA from malonyl-CoA was coupled to the citrate synthase/malate dehydrogenase reaction cycle leading to the NAD ϩ reduction (16) . The assay was performed at room temperature in 96-well microtiter plates, and the reaction was monitored spectrophotometrically at 340 nm after the formation of NADH. A typical reaction mixture (100 l) contained 100 mM Tris⅐Cl (pH 8.0), 10 mM L-malate, 0.5 mM NAD ϩ , 0.6 mg of BSA, 6.8 units/ml (0.1 mg/ml) citrate synthase, 3.6 units/ml (0.07 mg/ml) malic dehydrogenase, biocytin (standard assay concentrations, 5 mM) and malonyl-CoA (standard assay concentration, 0.1 mM). The reaction was initiated by the addition of CT. To determine the kinetic parameters of the enzymatic reaction, initial velocities were obtained by varying the substrate concentrations (biocytin and malonyl-CoA). The data were calculated by nonlinear regression of initial velocity values and substrate concentrations and fit to the Michaelis-Menten equation by using GraphPad Prism 5 software (GraphPad Software). For andrimid-inhibition assays, the initial velocity of the enzyme activities was determined in the presence of various concentrations of andrimid under standard assay conditions. IC50 values were obtained by fitting the data to a sigmoid dose-response equation by using the GraphPad Prism software. 
Supporting Information

